About
Definium Therapeutics, formerly known as MindMed, is a pioneering clinical-stage biopharmaceutical company at the forefront of psychedelic medicine. The company is dedicated to developing novel therapeutics that address the root causes of psychiatric conditions such as Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), and Autism Spectrum Disorder (ASD). Their lead candidate, DT120 ODT, is a proprietary pharmaceutically optimized formulation of lysergide (LSD) D-tartrate in an orally disintegrating tablet form. DT120 ODT is designed to increase neural connectivity between brain regions, potentially treating depression, anxiety, and other health disorders. Their second candidate, DT402, is the R-enantiomer of MDMA, selected for its serotonergic properties and promising prosocial effects with a favorable tolerability profile, targeting core symptoms of autism spectrum disorder. Definium Therapeutics operates with a science-first philosophy, emphasizing transparency, rigorous clinical trials, and a deep commitment to transforming patient outcomes. With an estimated 26 million U.S. adults living with GAD, 41 million with MDD, and 5.4 million with ASD, the company is targeting massive unmet medical needs. It is publicly traded and engages investors, researchers, and healthcare stakeholders with open reporting, SEC filings, and regular clinical updates.
Key Features
- DT120 ODT (LSD-Derived Therapeutic): A proprietary orally disintegrating tablet formulation of lysergide (LSD) D-tartrate designed to enhance neural connectivity and treat depression and anxiety disorders.
- DT402 (R-MDMA for ASD): A novel R-enantiomer of MDMA developed to target the core social communication symptoms of Autism Spectrum Disorder with a favorable tolerability profile.
- Active Clinical Trial Pipeline: Ongoing clinical trials advancing psychiatric treatments beyond current standards, targeting GAD, MDD, and ASD in large adult patient populations.
- Root-Cause Treatment Approach: Focuses on solving the underlying neurological and biological causes of psychiatric conditions rather than merely managing symptoms.
- Transparent Scientific Reporting: Publicly traded company with full investor transparency, including SEC filings, clinical data releases, and corporate governance documentation.
Use Cases
- Patients with treatment-resistant Generalized Anxiety Disorder (GAD) seeking novel therapeutic options beyond traditional medications.
- Adults living with Major Depressive Disorder (MDD) who have not responded adequately to existing antidepressant treatments.
- Individuals with Autism Spectrum Disorder (ASD) and caregivers looking for therapies that address core social communication challenges.
- Researchers and clinicians studying the clinical potential of psychedelic-derived compounds in psychiatry.
- Investors and biotech stakeholders tracking the development of next-generation psychedelic medicine pipelines.
Pros
- Innovative Therapeutic Pipeline: Targets large underserved patient populations with novel psychedelic-derived compounds where existing treatments have largely failed.
- Rigorous Evidence-Based Science: All programs are grounded in preclinical and clinical evidence, with transparent reporting and active regulatory engagement.
- Dual Indication Coverage: Addresses three major psychiatric conditions — GAD, MDD, and ASD — with distinct, differentiated candidates.
Cons
- Early Clinical Stage Risk: As a clinical-stage company, no products are yet approved or commercially available, carrying inherent development and regulatory risk.
- Regulatory Complexity: Psychedelic-derived compounds face significant regulatory hurdles and public perception challenges that may slow approval timelines.
- Limited Near-Term Availability: Patients seeking treatment cannot yet access these therapies outside of clinical trial settings.
Frequently Asked Questions
What is Definium Therapeutics (formerly MindMed)?
Definium Therapeutics is a clinical-stage biopharmaceutical company developing psychedelic medicine-based treatments for psychiatric disorders including anxiety, depression, and autism spectrum disorder.
What is DT120 ODT?
DT120 ODT is a proprietary orally disintegrating tablet formulation of lysergide (LSD) D-tartrate. It is designed to increase connections between brain regions to help treat depression, anxiety, and other health disorders.
What is DT402 and who is it for?
DT402 is the R-enantiomer of MDMA, being developed to target core social communication symptoms of Autism Spectrum Disorder (ASD), with a potentially superior tolerability profile compared to racemic MDMA.
What conditions does Definium Therapeutics target?
The company is developing treatments for Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), and Autism Spectrum Disorder (ASD) — conditions affecting tens of millions of adults in the U.S.
How can I participate in a clinical trial?
Information about ongoing clinical trials is available on the Definium Therapeutics website under the Clinical Trials section. Interested individuals can review eligibility criteria and contact the company for enrollment details.
